Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) [Yahoo! Finance]
Immuneering Corporation - Class A (IMRX)
Company Research
Source: Yahoo! Finance
their ‘Outperform' rating on Immuneering Corporation (NASDAQ:IMRX), while maintaining a price target of $10, implying a surge of about 43%. This optimism stems from the company's positive clinical trial outcome for its lead drug candidate. On Wednesday, Immuneering Corporation (NASDAQ:IMRX) reported modified 9-month survival data from its Phase 2a trial of atebimetinib (atebi), together with updated gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. The data, collected from 34 patients, reflected overall survival and progression-free survival results that not only surpassed the traditional standard-of-care treatments, but also the research firm's own expectations. BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang's Stock Picks with Huge Upside Potential What keeps the investor's interest is the company's atebimetinib, which has the potential to become a top-tier treatment for first-line pancreatic cancer patients. With the results demonstrating enhanced durabili
Show less
Read more
Impact Snapshot
Event Time:
IMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRX alerts
High impacting Immuneering Corporation - Class A news events
Weekly update
A roundup of the hottest topics
IMRX
News
- Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Immuneering to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Immuneering (NASDAQ:IMRX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
- Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.MarketBeat
- Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
IMRX
Earnings
- 11/12/25 - Miss
IMRX
Sec Filings
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- 10/21/25 - Form SCHEDULE
- IMRX's page on the SEC website